-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 29.5%
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 29.5%
Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Rating) saw a significant growth in short interest in the month of December. As of December 30th, there was short interest totalling 395,000 shares, a growth of 29.5% from the December 15th total of 305,100 shares. Approximately 3.0% of the company's stock are short sold. Based on an average daily volume of 38,000 shares, the short-interest ratio is currently 10.4 days.
Institutional Trading of Vigil Neuroscience
Hedge funds have recently made changes to their positions in the stock. BVF Inc. IL acquired a new stake in Vigil Neuroscience in the third quarter worth $16,504,000. Rock Springs Capital Management LP bought a new stake in Vigil Neuroscience in the 1st quarter valued at about $3,318,000. Vanguard Group Inc. acquired a new position in Vigil Neuroscience during the 1st quarter valued at about $2,708,000. BlackRock Inc. acquired a new position in Vigil Neuroscience during the 1st quarter valued at about $2,135,000. Finally, Laurion Capital Management LP acquired a new stake in shares of Vigil Neuroscience in the second quarter valued at approximately $336,000. Institutional investors own 88.91% of the company's stock.
Get Vigil Neuroscience alerts:Vigil Neuroscience Price Performance
VIGL traded down $0.02 during trading hours on Thursday, hitting $11.76. 1,556 shares of the stock were exchanged, compared to its average volume of 23,566. The stock has a market cap of $418.43 million and a price-to-earnings ratio of -1.18. Vigil Neuroscience has a 12 month low of $2.18 and a 12 month high of $18.27. The stock has a 50-day simple moving average of $11.78 and a 200-day simple moving average of $10.00.
Vigil Neuroscience (NASDAQ:VIGL – Get Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06. Sell-side analysts expect that Vigil Neuroscience will post -2.25 EPS for the current year.Analyst Ratings Changes
Several equities research analysts recently issued reports on the stock. Guggenheim dropped their price target on shares of Vigil Neuroscience from $22.00 to $19.00 and set a "buy" rating on the stock in a research note on Friday, November 11th. Morgan Stanley raised their price objective on Vigil Neuroscience from $11.00 to $12.00 and gave the company an "equal weight" rating in a research note on Monday, November 14th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Vigil Neuroscience currently has an average rating of "Moderate Buy" and an average target price of $19.67.
About Vigil Neuroscience
(Get Rating)
Vigil Neuroscience, Inc, a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease.
See Also
- Get a free copy of the StockNews.com research report on Vigil Neuroscience (VIGL)
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
- 3 Attractive Defensive Stocks With 3% Dividends
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
维吉尔神经科学公司(纳斯达克:VIGL-GET评级)在12月份看到空头股数的显著增长。截至12月30日,空头股数共有39.5万股,比12月15日的30.51万股增长29.5%。该公司约3.0%的股票被卖空。以日均成交量38,000股计算,目前短息比率为10.4天。
维吉尔神经科学的机构交易
对冲基金最近对其股票头寸进行了调整。BVF Inc.IL在第三季度收购了Vigil NeuroScience价值16,504,000美元的新股份。Rock Springs Capital Management LP在第一季度购买了Vigil NeuroScience的新股份,价值约331.8万美元。先锋集团(Vanguard Group Inc.)在第一季度收购了维吉尔神经科学公司的一个新头寸,估值约为270.8万美元。贝莱德股份有限公司在第一季度收购了维吉尔神经科学公司的一个新头寸,价值约2,135,000美元。最后,Laurion Capital Management LP在第二季度收购了Vigil NeuroScience的新股份,价值约33.6万美元。机构投资者持有该公司88.91%的股票。
到达守夜神经科学警报:维基神经科学的价格表现
周四交易时段,Vigl股价下跌0.02美元,至11.76美元。该股共成交1,556股,而其平均成交量为23,566股。该股市值为4.1843亿美元,市盈率为-1.18倍。维吉尔神经科学的12个月低点为2.18美元,12个月高位为18.27美元。该股的50日简单移动均线切入位为11.78美元,200日简单移动均线切入位为10.00美元。
维吉尔神经科学(纳斯达克:VIGL-GET评级)上一次公布季度收益数据是在11月10日星期四。该公司公布本季度每股收益(0.53美元),比分析师普遍预期的(0.59美元)高出0.06美元。卖方分析师预计,Vigil NeuroScience本年度每股收益将达到2.25欧元。分析师评级发生变化
几位股票研究分析师最近发布了有关该股的报告。11月11日,古根海姆在一份研究报告中,将维吉尔神经科学公司的股票目标价从22.00美元下调至19.00美元,并对该股设定了“买入”评级。11月14日,周一,摩根士丹利在一份研究报告中将维吉尔神经科学的目标价从11.00美元上调至12.00美元,并给予该公司“同等权重”的评级。一名股票研究分析师将该股评级为持有,五名分析师将该公司股票的评级定为买入。根据MarketBeat的数据,Vigil NeuroScience目前的平均评级为“中等买入”,平均目标价为19.67美元.
关于维吉尔神经科学
(获取评级)
维吉尔神经科学公司是一家专注于小胶质细胞的公司,致力于为受到罕见和常见神经退行性疾病影响的患者、护理人员和家庭开发疾病修正疗法。它的主要候选产品是VGL101,这是一种完全人类的单抗(MAb),旨在激活髓样细胞2(TREM2)上表达的触发受体,该受体处于I期,用于治疗成人起病的轴突球体和有色胶质细胞,以及治疗大脑肾上腺脑白质营养不良和阿尔茨海默病。
另请参阅
- 免费获取StockNews.com关于Vigil神经科学的研究报告(Vigl)
- 爱彼迎的涨幅是否会像分析师预测的那样达到38%?
- 特斯拉汽车降价是否意味着特斯拉股票也会降价?
- 微软的裁员标志着其他科技公司的裁员?
- 快速购买Fastenal的原因不止一个
- 3只有吸引力的防御性股票,股息为3%
接受《维吉尔神经科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vigil NeuroScience和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧